Identity and synonyms
AT1001 also retrieves migalastat studies: exclude those from larazotide evidence.
Synonyms: Larazotide acetate · AT-1001 (ambiguous code)
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Investigational intestinal tight-junction modulation.
Evidence and critical reading
Reported scientific and empirical uses
Gut and barrier · Immune modulation and inflammation
Reported for intestinal permeability and GI symptoms; the specific trial addressed persistent celiac symptoms.
Human evidence
A 342-adult celiac trial found a symptom signal in one study arm; this does not establish efficacy in IBS or all permeability complaints.
Preclinical evidence
Barrier models do not establish a universal gut-repair effect.
Critical reading and limitations
A randomized 342-adult trial found a signal in one arm; it does not validate every “leaky gut” claim or replace a gluten-free diet.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.
0.5 / 1 / 2 mg · Per administration in separate arms
- Frequency
- Three times/day
- Duration
- 12 treatment weeks
- Route
- Oral
- Context
- 342 adults with symptomatic celiac disease despite diet; favorable signal only in 0.5-mg arm.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID25683116 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Trial tolerability and exclusions do not characterize long-term combination safety.
Trial tolerability is population/formulation-specific; BPC/KPV blends do not inherit those data.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID25683116 · Randomized controlled trial
Symptomatic celiac disease despite gluten-free diet.
Oral three times/day, 12 weeks.
0.5-mg arm met symptom endpoint; 1/2 mg did not differ from placebo.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 342
Trials attributed in the package
NCT03569007 · Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD SymptomsRegistry status: TerminatedLast update posted: July 26, 2022Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Larazotide · 29 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06904261 · A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsRegistry status: RecruitingLast update posted: September 1, 2026Query verification: October 16, 2026
NCT05747534 · AT1001 for the Treatment of Long COVIDRegistry status: CompletedLast update posted: August 18, 2026Query verification: October 16, 2026
NCT04020055 · A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseRegistry status: Active, not recruitingLast update posted: July 6, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID25683116
Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, Rasmussen H, Wang C, Bercik P, Bachir NM, Murray JA.
October 16, 2026
- R17